| Autor: |
Tzong-Yow Wu, Wan-Ting Tsai, Kai-Hsiang Chen, Szu-Ting Huang, Chun-Fu Huang, Po-Hsien Kuo, Ming-Jui Tsai, Wang-Da Liu, Kuan-Yin Lin, Yu-Shan Huang, Aristine Cheng, Pao-Yu Chen, Hsin-Yun Sun, Huai-Hsuan Huang, Tai-Chung Huang, Shang-Ju Wu, Ming Yao, Jann-Tay Wang, Wang-Huei Sheng, Chien-Ching Hung, Yee-Chun Chen, Shan-Chwen Chang |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Journal of Microbiology, Immunology and Infection, Vol 57, Iss 3, Pp 403-413 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1684-1182 |
| DOI: |
10.1016/j.jmii.2024.03.001 |
| Popis: |
Background: Patients with hematological malignancies (HM) were at a high risk of developing severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess the clinical outcome of COVID-19 in hospitalized patients with HM. Methods: Adult patients with HM who were hospitalized with a laboratory-confirmed COVID-19 between May, 2021 and November, 2022 were retrospectively identified. Primary outcome was respiratory failure requiring mechanical ventilation or mortality within 60 days after hospitalization. We also analyzed associated factors for de-isolation (defined as defervescence with a consecutive serial cycle threshold value > 30) within 28 days. Results: Of 152 eligible patients, 22 (14.5%) developed respiratory failure or mortality in 60 days. Factors associated with developing respiratory failure that required mechanical ventilation or mortality included receipt of allogeneic hematopoietic stem-cell transplantation (allo-HSCT) (adjusted hazards ratio [aHR], 5.10; 95% confidence interval [CI], 1.64–15.85), type 2 diabetes mellitus (aHR, 2.47; 95% CI, 1.04–5.90), lymphopenia at admission (aHR, 6.85; 95% CI, 2.45–19.15), and receiving |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
